Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$1.29 → $1.29 · observed estimates
Gencor Industries, Inc. (GENC)
AMEXIndustrialsIndustrial - MachinerySnapshot 2026-11-04
$17.55+1.80%
Close 2026-11-04 · 1-day change
AMEXIndustrialsIndustrial - MachinerySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.29 → 1.29 EPS · FY ending Sep 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for GENC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations improves to at least $6.9M by Q2 2026 | Cash from operations improved from -$23.9M to $6.9M. | Under Pressure | Cash flow falls below zero in any quarter | Cash from operations: $9.505M FY2026-Q3; GAAP. Published target: >= $6.9 million. Target period is not explicitly aligned with this observation. Aug 10, 20269,505,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$1.29 → $1.29 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 8, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a smaller-cap industrial business with a multi-year thesis built on backlog conversion and improved operating income. The thesis is intact, though execution is mixed and the sector backdrop is a headwind.
GENC is described as cheap versus peers, and its valuation measure has fallen recently. The pricing evidence labels expectations as justified, with low fragility, but does not show exactly what the market assumes about future results.
Near term, the record backlog supports management’s goal of sustaining performance into fiscal 2027, while recent revenue has been uneven and the latest cited quarter was down year over year. Operating income has improved from a prior-quarter loss and gross margins have strengthened, but inconsistent revenue growth and erratic earnings surprises remain risks.
The multi-year view depends on converting backlog into sustained revenue growth while continuing to improve operating income. Near term, a guidance cut would be a meaningful negative; results and guidance from industrial bellwethers could also strengthen or weaken the sector backdrop.
The long-term thesis remains intact, but backlog conversion and consistent growth are not yet proven, and management execution is mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. Cash from operating activities was positive in 2026-Q1 ($11.1 million) and 2026-Q2 ($6.9 million) but turned negative in 2026-Q3 (-$16.7 million). The cash flow trajectory is mixed with recent deterioration, indicating limited progress on consistent cash flow enhancement.
Operating income improves to at least $4.2M by Q2 2026 | Operating income rose from a loss to $4.2M. | Intact | Operating income falls below zero in any quarter | Operating income: $5.802M FY2026-Q3; GAAP. Published target: >= $4.2 million. Target period is not explicitly aligned with this observation. Aug 10, 20265,802,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 4 of last 4 quarters. Operating income improved from a loss of $0.2 million in 2025-Q4 to $5.8 million in 2026-Q3, despite a dip in 2026-Q2 due to higher trade show expenses. Gross margins improved, reflecting effective cost management. The trajectory shows delivering progress on operating income improvement. Delivery assessment Sep 15, 2026 |
Revenue grows to at least $33.8M by Q2 2026 | A primary condition in Gencor Industries, Inc.'s published investment case. The stated target is >= $33.8 million. | Under Pressure | Revenue falls below $18.8 million in any quarter | Revenue: $33.805M FY2026-Q3; GAAP. Published target: >= $33.8 million. Target period is not explicitly aligned with this observation. Aug 10, 202633,805,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 4 of last 4 quarters. Revenue increased from $18.8 million in 2025-Q4 to $33.8 million in 2026-Q3, though 2026-Q2 revenue declined year-over-year due to timing of orders. The backlog growth supports future revenue, but recent quarterly revenue shows a mixed trajectory with limited progress on consistent growth. Delivery assessment Sep 15, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.15B → $0.15B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-02 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-03 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-04 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-05 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-06 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-07 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-08 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-09 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-10 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-11 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-12 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-13 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-14 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-15 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-16 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-17 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-18 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-19 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-20 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-21 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-22 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-23 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-24 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-25 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-26 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-27 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-28 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-29 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-30 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-10-31 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-11-01 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-11-02 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-11-03 | $1.29 | $153,010,000 | 1 / 1 |
| 2026-11-04 | $1.29 | $153,010,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.